The Korean journal of internal medicine

  • 제29권5호
  • /
  • Pages.656-663
  • /
  • 2014
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials

  • Song, Gwan Gyu (Division of Rheumatology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Bae, Sang-Cheol (Hospital for Rheumatic Diseases, Hanyang University College of Medicine) ;
  • Lee, Young Ho (Division of Rheumatology, Department of Internal Medicine, Korea University College of Medicine)
  • 투고 : 2013.09.26
  • 심사 : 2013.12.23
  • 발행 : 2014.09.01
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: The aim of this study was to assess the efficacy and safety of tofacitinib (5 and 10 mg twice daily) in patients with active rheumatoid arthritis (RA). Methods: A systematic review of randomized controlled trials (RCTs) that examined the efficacy and safety of tofacitinib in patients with active RA was performed using the Medline, Embase, and Cochrane Controlled Trials Register databases as well as manual searches. Results: Five RCTs, including three phase-II and two phase-III trials involving 1,590 patients, met the inclusion criteria. The three phase-II RCTs included 452 patients with RA (144 patients randomized to 5 mg of tofacitinib twice daily, 156 patients randomized to 10 mg of tofacitinib twice daily, and 152 patients randomized to placebo) who were included in this meta-analysis. The American College of Rheumatology 20% response rate was significantly higher in the tofacitinib 5- and 10-mg groups than in the control group (relative risk [RR], 2.445; 95% confidence interval [CI], 1.229 to 4.861; p = 0.011; and RR, 2.597; 95% CI, 1.514 to 4.455; p = 0.001, respectively). The safety outcomes did not differ between the tofacitinib 5- and 10-mg groups and placebo groups with the exception of infection in the tofacitinib 10-mg group (RR, 2.133; 95% CI, 1.268 to 3.590; p = 0.004). The results of two phase-III trials (1,123 patients) confirmed the findings in the phase-II studies. Conclusions: Tofacitinib at dosages of 5 and 10 mg twice daily was found to be effective in patients with active RA that inadequately responded to methotrexate or disease-modifying antirheumatic drugs, and showed a manageable safety profile.

키워드

참고문헌

  1. Harris ED Jr. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990;322:1277-1289. https://doi.org/10.1056/NEJM199005033221805
  2. Choi SJ, Rho YH, Ji JD, Song GG, Lee YH. Genome scan meta-analysis of rheumatoid arthritis. Rheumatology (Oxford) 2006;45:166-170. https://doi.org/10.1093/rheumatology/kei128
  3. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009;228:273-287. https://doi.org/10.1111/j.1600-065X.2008.00754.x
  4. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003;302:875-878. https://doi.org/10.1126/science.1087061
  5. Chrencik JE, Patny A, Leung IK, et al. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. J Mol Biol 2010;400:413-433. https://doi.org/10.1016/j.jmb.2010.05.020
  6. Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/ JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010;7:41. https://doi.org/10.1186/1476-9255-7-41
  7. Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH; Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011;63:1150-1158.
  8. Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012;64:617-629. https://doi.org/10.1002/art.33383
  9. Kremer JM, Cohen S, Wilkinson BE, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 2012;64:970-981. https://doi.org/10.1002/art.33419
  10. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-519. https://doi.org/10.1056/NEJMoa1112072
  11. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495-507. https://doi.org/10.1056/NEJMoa1109071
  12. Traynor K. FDA approves tofacitinib for rheumatoid arthritis. Am J Health Syst Pharm 2012;69:2120.
  13. Lee YH, Woo JH, Choi SJ, Ji JD, Bae SC, Song GG. Tacrolimus for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Scand J Rheumatol 2010;39:271-278. https://doi.org/10.3109/03009740903501642
  14. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG. Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta- analysis. Rheumatol Int 2006;27:157-161. https://doi.org/10.1007/s00296-006-0175-7
  15. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634. https://doi.org/10.1136/bmj.315.7109.629
  16. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ 1997;315:1533-1537. https://doi.org/10.1136/bmj.315.7121.1533
  17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188. https://doi.org/10.1016/0197-2456(86)90046-2
  18. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558. https://doi.org/10.1002/sim.1186
  19. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009;60:1895-1905. https://doi.org/10.1002/art.24567
  20. Coombs JH, Bloom BJ, Breedveld FC, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2010;69:413-416. https://doi.org/10.1136/ard.2009.108159
  21. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-2219. https://doi.org/10.1056/NEJMra1004965

피인용 문헌

  1. Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA? vol.29, pp.5, 2014, https://doi.org/10.3904/kjim.2014.29.5.577
  2. Posicionamento sobre o uso de tofacitinibe no algoritmo do Consenso 2012da Sociedade Brasileira de Reumatologia para o tratamento da artrite reumatoide vol.55, pp.6, 2014, https://doi.org/10.1016/j.rbr.2015.08.004
  3. Impact of tofacitinib on patient outcomes in rheumatoid arthritis – review of clinical studies vol.7, pp.None, 2014, https://doi.org/10.2147/prom.s62879
  4. Biologic Therapies for Autoimmune and Connective Tissue Diseases vol.37, pp.2, 2014, https://doi.org/10.1016/j.iac.2017.01.005
  5. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoin vol.69, pp.8, 2014, https://doi.org/10.1002/acr.23274
  6. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoin vol.69, pp.8, 2014, https://doi.org/10.1002/art.40149
  7. Histamine and Histamine H4 Receptor Promotes Osteoclastogenesis in Rheumatoid Arthritis vol.7, pp.None, 2017, https://doi.org/10.1038/s41598-017-01101-y
  8. Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors vol.13, pp.12, 2017, https://doi.org/10.1371/journal.ppat.1006740
  9. Chronic Pain in Inflammatory Arthritis: Mechanisms, Metrology, and Emerging Targets—A Focus on the JAK-STAT Pathway vol.2018, pp.None, 2018, https://doi.org/10.1155/2018/8564215
  10. An overview of meta-analysis for clinicians vol.33, pp.2, 2014, https://doi.org/10.3904/kjim.2016.195
  11. Efficacy and safety of baricitinib for active rheumatoid arthritis in patients with an inadequate response to conventional synthetic or biological disease-modifying anti-rheumatic drugs: A meta-analys vol.16, pp.3, 2018, https://doi.org/10.3892/etm.2018.6495
  12. N -acetyl-l-cysteine controls osteoclastogenesis through regulating Th17 differentiation and RANKL in rheumatoid arthritis vol.34, pp.1, 2014, https://doi.org/10.3904/kjim.2016.329
  13. Comparative efficacy and safety of 15 and 30 mg upadacitinib administered to patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials vol.79, pp.1, 2014, https://doi.org/10.1007/s00393-019-0601-3
  14. Comparison of the efficacy and safety of tofacitinib and peficitinib in patients with active rheumatoid arthritis: A Bayesian network meta‐analysis of randomized controlled trials vol.23, pp.7, 2014, https://doi.org/10.1111/1756-185x.13854
  15. Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials vol.79, pp.6, 2020, https://doi.org/10.1007/s00393-019-00733-x
  16. Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials vol.79, pp.6, 2020, https://doi.org/10.1007/s00393-019-00733-x
  17. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis vol.79, pp.8, 2014, https://doi.org/10.1007/s00393-020-00750-1